Loading...
XNAS
EOLS
Market cap451mUSD
Jul 09, Last price  
6.85USD
1D
0.88%
1Q
60.42%
IPO
-41.25%
Name

Evolus Inc

Chart & Performance

D1W1MN
XNAS:EOLS chart
P/E
—
P/S
1.52
EPS
—
Div Yield, %
—
Shrs. gr., 5y
13.83%
Rev. gr., 5y
39.36%
Revenues
297m
+11.61%
000034,925,00056,540,00099,673,000148,616,000202,085,000266,274,000297,176,000
Net income
-52m
L+2.42%
-31,112,000-20,065,000-4,480,000-46,867,000-90,034,000-163,013,000-46,810,000-74,412,000-61,685,000-50,420,000-51,641,000
CFO
-42m
L+134.82%
-36,384,000-13,267,000-13,035,000-25,667,000-93,383,000-57,871,000-33,388,000-84,912,000-34,008,000-17,999,000-42,265,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Evolus, Inc. functions as a performance beauty specialist, supplying medical aesthetic solutions to healthcare practitioners and their patients across the United States. Central to its offerings is Jeuveau, an exclusive formulation of 900 kilodalton purified botulinum toxin type A. This product is specifically engineered to offer a temporary improvement in the appearance of moderate to severe frown lines in adults. The firm was established in 2012 and maintains its primary office in Newport Beach, California.
URL
https://www.evolus.com
IPO date
Feb 08, 2018
Employees
215
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT